Potent anxiolytic effects
clinical
0 views
Adalank
Adalank (N-Acetyl Selank Amidate) is an enhanced synthetic derivative of Selank peptide, featuring N-terminal acetylation and C-terminal amidation for superior stability and blood-brain barrier penetration.
Overview
Adalank (N-Acetyl Selank Amidate) is an enhanced synthetic derivative of Selank peptide, featuring N-terminal acetylation and C-terminal amidation for superior stability and blood-brain barrier penetration. Developed from the immunomodulatory peptide tuftsin, it's researched for anxiety reduction, cognitive enhancement, neuroprotection, and stress resilience with improved pharmacokinetic properties compared to the parent compound.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
Selank analogSelank derivative
Status: Research compound - Not FDA-approved; approved for clinical use in Russia since early 2000s
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Anxiety and stress modulation (proposed)Cognitive enhancement (proposed)
Available Evidence
Uncertain
Adalank is sold as a research-grade Selank analog, but no peer-reviewed, PubMed-indexed studies specific to Adalank were located. Anxiolytic/nootropic claims are extrapolated from the parent compound Selank, a tuftsin-derived heptapeptide studied in Russia for anxiety disorders.
Benefits & Effects
enhanced cognitive function
clinical
stress resilience
clinical
improved mood and emotional stability
clinical
neuroprotection
clinical
immunomodulatory support
clinical
Superior bioavailability and extended half-life compared to parent compound Selank
clinical
No side effects data available yet.
This peptide may have limited safety data.
Limitations & Open Questions
No reliable published evidence for Adalank itself: no PubMed results, no clinical trials, no peer-reviewed animal or cell studies. All available information comes from peptide vendor product pages and chemical suppliers; identity, stability, dosing and safety are unverified.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
200-300mcg
Route: Injectable
Half-life: 4-6 hours (extended vs. parent Selank)
Research Protocols
Anxiety reduction
- Dose
- 200-300mcg
- Frequency
- 1x daily (morning)
- Route
- SubQ
Cognitive enhancement
- Dose
- 200-500mcg
- Frequency
- 1x daily
- Route
- SubQ
Stress management
- Dose
- 200-300mcg
- Frequency
- 2x daily (morning, afternoon)
- Route
- SubQ
Initial assessment/trial
- Dose
- 100-200mcg
- Frequency
- 1x daily
- Route
- SubQ
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is Adalank the same as Selank?
No. Adalank is marketed as an analog/derivative of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a tuftsin-related heptapeptide with Russian clinical studies in anxiety. Adalank-specific research is essentially absent from the peer-reviewed literature.
Has Adalank been studied in clinical trials?
No clinical trials for Adalank were found. Vendor-published 'protocols' are not clinical evidence.
Research Citations
1
Selank and BDNF Regulation in Hippocampus (Parent Compound)
()
2
Peptide Selank Enhances Diazepam Effects in Stress (Parent Compound)
()
3
Selank and GABAergic Neurotransmission Gene Expression (Parent Compound)
()
Related Resources
Quick Facts
Molecular Weight
792.93
Mechanism
Adalank crosses the blood-brain barrier via enhanced lipophilicity from N-acetylation and C-terminal amidation. It modulates GABAergic neurotransmission, upregulates BDNF in the hippocampus, influences serotonin metabolism, provides immunomodulatory effects via tuftsin-derived mechanisms, and reduces stress-related neurotransmitters without benzodiazepine dependency.
Safety Information
Use sterile injection technique to prevent infection. CRITICAL: This is an experimental peptide with limited direct human research data on N-Acetyl form. Parent compound Selank has extensive Russian clinical research showing high safety profile. No tolerance, dependency, or withdrawal unlike benzodiazepines. Start with lower doses (100-200mcg) to assess individual response. Cycle usage with 1-2 week breaks to prevent potential tolerance. Not FDA-approved; approved for clinical use in Russia since early 2000s. Not recommended during pregnancy or breastfeeding due to lack of safety data. Consult healthcare provider before use, especially with other psychiatric medications.
Citations
31.Selank and BDNF Regulation in Hippocampus (Parent Compound)
()
2.Peptide Selank Enhances Diazepam Effects in Stress (Parent Compound)
()
3.Selank and GABAergic Neurotransmission Gene Expression (Parent Compound)
()